New data presented to the Annual Meeting of the American College of Allergy, Asthma and Immunology suggest the discovery of a potential diagnostic tool and therapeutic measurement for CFS.
The Centers for Disease Control and Prevention, report that chronic fatigue symptoms affect more than 14 million people between the ages of 17-69 and in twice as many women as men. "Currently, the diagnosis of CFS involves a lengthy procedure of eliminating other possible causes of severe fatigue lasting more than six consecutive months," said Dr. Joseph Bellanti, M.D., and Director of the International Center for Interdisciplinary Studies of Immunology at Georgetown University Medical Center, who identified a simple-to-test for urinary marker in CFS patients.
Last month a study published in the American Medical Association's The Archives of Internal Medicine reported that the incidence of CFS is significantly more prevalent than previous data suggests. The study reported women are 20 times more likely to develop CFS than breast cancer and more than 15 times more likely to contract CFS than lung cancer.
CFS patients suffer a debilitating illness that drastically affects their ability to work and live normal lives. CFS patients are often unable to complete the simplest of tasks without being exhausted. "Dr. Bellanti's work may represent a major breakthrough that will help doctors provide earlier diagnosis and better treatment," said Dr. Georg Birkmayer, M.D., Ph.D., the researcher who first discovered the therapeutic application of NADH in cellular development and energy transmission. NADH is a naturally occurring coenzyme that activates bodily energy production.
The Georgetown University Medical Center doctors' groundbreaking CFS research involved the use of ENADA NADH a dietary supplement. Results of an FDA approved, double-blind, placebo-controlled cross-over study published in the February 1999 issue of Annals of Allergy, Asthma and Immunology found that CFS patients taking ENADA, a dietary supplement, were four times more likely to show improvements compared to those taking a placebo. A follow-up open label study showed 72% of the patients taking ENADA achieved continued marked improvement over time. After more than 18 months of using ENADA more than 80% of the CFS patients continue to experience improvement in their condition.
Dr. Bellanti's current study evaluated of 20 of the original CFS test subjects and found that 75 percent showed elevated levels of a major breakdown metabolite product of seratonin, 5-HIAA which appears in urine. When treated with NADH, 70 percent of the patients returned to the normal range. In subjects taking a placebo, 70 percent retained elevated or increased levels of 5-HIAA.
Dr. Bellanti is founder and director of Georgetown University Medical Center's International Center for Interdisciplinary Studies of Immunology. He is a professor of pediatrics and microbiology. Dr. Bellanti has served on the Maternal and Child Health Study Section of the National institutes of Child Health and Human Development (NICHD) and the Allergy and Immunology Research Committee of the National Institute of Allergy and Infectious Diseases NIAID). He has published more than 400 scientific papers, abstracts and books. He is the author of the widely renowned textbook on immunology, now in its third edition.
ENADA is the only patented, stabilized, absorbable, oral form of NADH available.